Showing results (111-120 of 138) with videos related to

Sort By:
Pageof 14
American Journal of Clinical Dermatology|February 19, 2026
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and TreatmentsCaitlin A Kearney, Anna L Brinks, Carli Needle Lawrence, et al.
The Journal of Rheumatology|September 17, 2014
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonistMark C Genovese, Désirée M van der Heijde, Edward C Keystone, et al.
International Journal of Cancer|September 11, 2014
Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three-dimensional genetic models of ovarian carcinogenesisKate Lawrenson, Paulette Mhawech-Fauceglia, Jenny Worthington, et al.
Nature Genetics|June 16, 2015
Genome-wide significant risk associations for mucinous ovarian carcinomaLinda E Kelemen, Kate Lawrenson, Jonathan Tyrer, et al.
Mabs|March 23, 2019
Antibody repertoire analysis of mouse immunization protocols using microfluidics and molecular genomicsMichael A Asensio, Yoong Wearn Lim, Nicholas Wayham, et al.
Mabs|January 30, 2018
A natively paired antibody library yields drug leads with higher sensitivity and specificity than a randomly paired antibody libraryAdam S Adler, Daniel Bedinger, Matthew S Adams, et al.
The Journal of Rheumatology|February 2, 2021
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis ProgramsArthur Kavanaugh, Rene R Westhovens, Kevin L Winthrop, et al.
Advances in Virology|January 28, 2012
Prevalence of XMRV nucleic acid and antibody in HIV-1-Infected men and in men at risk for HIV-1 InfectionJ Spindler, J Hackett, X Qiu, et al.
Stem Cell Reports|June 9, 2015
The Genetic Landscape of Hematopoietic Stem Cell Frequency in MiceXiaoying Zhou, Amanda L Crow, Jaana Hartiala, et al.
Annals of the Rheumatic Diseases|September 28, 2016
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trialDaniel J Wallace, Vibeke Strand, Joan T Merrill, et al.
Pageof 14